Assertio (NASDAQ:ASRT – Get Free Report) and Profound Medical (NASDAQ:PROF – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.
Institutional & Insider Ownership
49.0% of Assertio shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 5.7% of Assertio shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Assertio and Profound Medical”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Assertio | $118.71 million | 1.28 | -$30.38 million | ($5.69) | -4.13 |
| Profound Medical | $16.10 million | 16.79 | -$42.57 million | ($1.24) | -6.00 |
Assertio has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Assertio has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Assertio and Profound Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Assertio | 1 | 4 | 0 | 0 | 1.80 |
| Profound Medical | 1 | 0 | 1 | 0 | 2.00 |
Assertio currently has a consensus price target of $22.65, indicating a potential downside of 3.62%. Profound Medical has a consensus price target of $12.00, indicating a potential upside of 61.29%. Given Profound Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Profound Medical is more favorable than Assertio.
Profitability
This table compares Assertio and Profound Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Assertio | -34.94% | -38.72% | -13.32% |
| Profound Medical | -206.76% | -78.88% | -64.06% |
Summary
Assertio beats Profound Medical on 8 of the 14 factors compared between the two stocks.
About Assertio
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with MarketBeat.com's FREE daily email newsletter.
